236 related articles for article (PubMed ID: 17546762)
1. [Genetics of Fabry disease: diagnostic and therapeutic implications].
Germain DP
Presse Med; 2007 Mar; 36 Spec No 1():1S14-9. PubMed ID: 17546762
[TBL] [Abstract][Full Text] [Related]
2. [Fabry's disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects].
Germain DP
J Soc Biol; 2002; 196(2):161-73. PubMed ID: 12360745
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
Germain DP; Poenaru L
Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
[TBL] [Abstract][Full Text] [Related]
4. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives].
Germain DP
Rev Med Interne; 2000 Dec; 21(12):1086-103. PubMed ID: 11191676
[TBL] [Abstract][Full Text] [Related]
5. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
[TBL] [Abstract][Full Text] [Related]
8. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
9. Identification of mutations in Colombian patients affected with Fabry disease.
Uribe A; Mateus HE; Prieto JC; Palacios MF; Ospina SY; Pasqualim G; da Silveira Matte U; Giugliani R
Gene; 2015 Dec; 574(2):325-9. PubMed ID: 26297554
[TBL] [Abstract][Full Text] [Related]
10. Disease manifestations and X inactivation in heterozygous females with Fabry disease.
Maier EM; Osterrieder S; Whybra C; Ries M; Gal A; Beck M; Roscher AA; Muntau AC
Acta Paediatr Suppl; 2006 Apr; 95(451):30-8. PubMed ID: 16720462
[TBL] [Abstract][Full Text] [Related]
11. X-chromosome inactivation in female patients with Fabry disease.
Echevarria L; Benistan K; Toussaint A; Dubourg O; Hagege AA; Eladari D; Jabbour F; Beldjord C; De Mazancourt P; Germain DP
Clin Genet; 2016 Jan; 89(1):44-54. PubMed ID: 25974833
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease: a new approach for the screening of females in high-risk groups.
Pasqualim G; Simon L; Sperb-Ludwig F; Burin MG; Michelin-Tirelli K; Giugliani R; Matte U
Clin Biochem; 2014 May; 47(7-8):657-62. PubMed ID: 24582695
[TBL] [Abstract][Full Text] [Related]
13. Fabry Disease: prevalence of affected males and heterozygotes with pathogenic
Doheny D; Srinivasan R; Pagant S; Chen B; Yasuda M; Desnick RJ
J Med Genet; 2018 Apr; 55(4):261-268. PubMed ID: 29330335
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG).
Ashton-Prolla P; Ashley GA; Giugliani R; Pires RF; Desnick RJ; Eng CM
Am J Med Genet; 1999 Jun; 84(5):420-4. PubMed ID: 10360396
[TBL] [Abstract][Full Text] [Related]
16. New mutations in the GLA gene in Brazilian families with Fabry disease.
Turaça LT; Pessoa JG; Motta FL; Muñoz Rojas MV; Müller KB; Lourenço CM; Junior Marques W; D'Almeida V; Martins AM; Pesquero JB
J Hum Genet; 2012 Jun; 57(6):347-51. PubMed ID: 22551898
[TBL] [Abstract][Full Text] [Related]
17. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.
Dobrovolny R; Dvorakova L; Ledvinova J; Magage S; Bultas J; Lubanda JC; Elleder M; Karetova D; Pavlikova M; Hrebicek M
J Mol Med (Berl); 2005 Aug; 83(8):647-54. PubMed ID: 15806320
[TBL] [Abstract][Full Text] [Related]
18. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
19. Mutation identification of Fabry disease in families with other lysosomal storage disorders.
Zampetti A; Fania L; Antuzzi D; Giurdanella F; Gnarra M; Bertola F; Lualdi S; Filocamo M; Morrone A; Feliciani C
Clin Genet; 2013 Sep; 84(3):281-5. PubMed ID: 23210910
[TBL] [Abstract][Full Text] [Related]
20. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
Sakuraba H
Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
